Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 13, 2023

SELL
$80.93 - $108.63 $40,465 - $54,315
-500 Reduced 27.78%
1,300 $134,000
Q2 2022

Aug 11, 2022

SELL
$71.48 - $86.85 $3.36 Million - $4.08 Million
-47,000 Reduced 96.31%
1,800 $155,000
Q4 2021

Feb 09, 2022

BUY
$71.72 - $91.47 $3.5 Million - $4.46 Million
48,800 New
48,800 $4.31 Million

Others Institutions Holding BMRN

About BIOMARIN PHARMACEUTICAL INC


  • Ticker BMRN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,824,000
  • Market Cap $12.4B
  • Description
  • BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...
More about BMRN
Track This Portfolio

Track Alan B. Lancz & Associates, Inc. Portfolio

Follow Alan B. Lancz & Associates, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Alan B. Lancz & Associates, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Alan B. Lancz & Associates, Inc. with notifications on news.